Position in ABVX
as of Jun 30, 2026
· filed Aug 4, 2026
Position Value
$34,338,170
-$433,539 QoQ
Shares Held
257,678
-17.5% QoQ
Ownership
0.295%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#47
of 302 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ABVX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026PRINCIPAL FINANCIAL GROUP INC holds $1,852,088,599 across 105 Biotechnology names. ABVX ranks #17 (1.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ASND |
Ascendis Pharma A/S
|
873,502 | $232,980,453 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
389,511 | $193,481,798 | |
| 3 | CYTK |
Cytokinetics Inc
|
1,311,664 | $111,740,655 | |
| 4 | GPCR |
Structure Therapeutics Inc.
|
1,752,753 | $94,070,253 | |
| 5 | INSM |
INSMED Inc
|
856,126 | $91,280,154 | |
| 6 | AXSM |
Axsome Therapeutics, Inc.
|
332,642 | $81,420,782 | |
| 7 | BBIO |
BridgeBio Pharma, Inc.
|
1,024,423 | $76,299,024 | |
| 8 | REGN |
Regeneron Pharmaceuticals, Inc.
|
121,053 | $75,481,386 |
All Filings in ABVX
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $34,338,170 | 257,678 | Shares | Defined | 2026-08-04 | |
| 2026-03-31 | $34,771,709 | 312,274 | Shares | Defined | 2026-05-04 | |
| 2025-12-31 | $29,383,555 | 217,890 | Shares | Defined | 2026-02-02 | |
| No filing history on record for this holder in this stock. | ||||||